MCID: INT060
MIFTS: 34

Intestinal Atresia malady

Category: Gastrointestinal diseases

Aliases & Classifications for Intestinal Atresia

About this section

Summaries for Intestinal Atresia

About this section
Wikipedia:68 Intestinal atresia is a malformation where there is a narrowing or absence of a portion of the... more...

MalaCards based summary: Intestinal Atresia is related to umbilical cord ulceration and intestinal atresia and pancreatic hypoplasia, intestinal atresia, and gallbladder aplasia or hypoplasia, with or without tracheoesophageal fistula. An important gene associated with Intestinal Atresia is TTC7A (Tetratricopeptide Repeat Domain 7A), and among its related pathways are Heart Development and Regulation of beta-cell development. Affiliated tissues include liver, breast and brain, and related mouse phenotypes are limbs/digits/tail and renal/urinary system.

Related Diseases for Intestinal Atresia

About this section

Graphical network of the top 20 diseases related to Intestinal Atresia:



Diseases related to intestinal atresia

Symptoms for Intestinal Atresia

About this section

Drugs & Therapeutics for Intestinal Atresia

About this section

Drugs for Intestinal Atresia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bosentanapproved, investigationalPhase 2100147536-97-8104865
Synonyms:
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
Bosentan
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
Bosentanum
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
D07538
 
DB00559
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
P-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
PDSP1_001731
PDSP2_001714
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
bosentanum
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
2Liver ExtractsPhase 23572
3Antihypertensive AgentsPhase 23618
4Endothelin Receptor AntagonistsPhase 2189
5
BilirubinPhase 2103635-65-45280352
Synonyms:
(4Z,15Z)-Bilirubin IXa
(Z,Z)-Bilirubin IXa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
 
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
Bilirubin
Bilirubin IX-alpha
Cholerythrin
Hematoidin
6Fat Emulsions, IntravenousPhase 229
7Hormone AntagonistsPhase 1, Phase 210002
8HormonesPhase 1, Phase 211748
9Glucagon-Like Peptide 1Phase 1, Phase 2620
10IncretinsPhase 1, Phase 21326
11Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 1, Phase 29988
12Gastrointestinal AgentsPhase 1, Phase 26401
13glucagonPhase 1, Phase 2379
14Soy BeanNutraceuticalPhase 2455
15Omega 3 Fatty AcidNutraceuticalPhase 2912
16
VancomycinapprovedPhase 13051404-90-6441141, 14969
Synonyms:
(1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-Oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
(2.2Sp,3.5sa,2.6sp)-O(4.2),C(3.4):c(5.4),O(4.6):c(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
1404-90-6
1404-93-9 (hydrochloride)
64685-75-2 (sulfate)
AC1L24VU
AC1L9AMI
AC1Q29OH
BIDD:GT0353
C06689
C66H75Cl2N9O24
CHEBI:28001
CHEMBL262777
CID14969
CID441141
CID5311496
CID6426898
CID6917992
D00212
DB00512
EINECS 215-772-6
HSDB 3262
LMPK14000004
LS-161387
 
Lopac0_001267
MolPort-001-794-649
NCGC00162383-02
Prestwick0_000497
Prestwick1_000497
Prestwick2_000497
SPBio_002314
UNII-6Q205EH1VU
VAN
VANCOMYCIN
Vancocin
Vancocin (TN)
Vancocin HCL
Vancomicina
Vancomicina [INN-Spanish]
Vancomycin
Vancomycin (USP)
Vancomycin HCL
Vancomycin Hydrochloride
Vancomycin [USAN:INN:BAN]
Vancomycine
Vancomycine [INN-French]
Vancomycinum
Vancomycinum [INN-Latin]
nchembio.350-comp1
17Anti-Bacterial AgentsPhase 19140
18Anti-Infective AgentsPhase 117220
19
Neomycinapproved421404-04-28378
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
BPBio1_000326
BRN 0101621
BSPBio_000296
C01737
C23H46N6O13
C25H50N6O13
CCRIS 5462
CHEBI:7508
CID8378
Caswell No. 595
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
D05140
DB00452
DB00994
EINECS 204-292-2
EINECS 215-766-3
EPA Pesticide Chemical Code 006303
Endomixin
Enterfram
Fradiomycin
Fradiomycin B
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
Framygen
 
Fraquinol
HMS2089P15
HSDB 3242
LS-96091
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Myciguent
N1142_SIGMA
NCGC00179612-01
NEOMYCIN AND POLYMYXIN B SULFATES
NEOMYCIN B
NEOMYCIN SULFATE
NMY
Neo-Fradin
Neo-Rx
Neo-fradin
Neobiotic
Neobrettin
Neolate
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomycin B Sulfate
Neomycin B sulfate
Neomycin Sulfate
Neomycin Sulphate
Neomycin solution
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Nivemycin
PIMAVECORT
Prestwick3_000158
ST075177
Soframycin
Soframycin Ophthalmic
Soframycine
Theraplusplus Plus
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
VONAMYCIN
Vonamycin powder V
neomycin
20Vitamins3857
21Trace Elements3900
22Pharmaceutical Solutions7004
23Micronutrients3901
24Alpha 1-Antitrypsin87
25Protein C Inhibitor85
26Bile Acids and Salts86
27alanineNutraceutical106
28lysineNutraceutical77
29glutamineNutraceutical144
30AcidophilusNutraceutical482
31ColaNutraceutical1768

Interventional clinical trials:

(show all 17)
idNameStatusNCT IDPhase
1Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.CompletedNCT01292551Phase 2
2Compassionate Use of Omegaven in ChildrenRecruitingNCT02370251Phase 2
3Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal FailureTerminatedNCT01573286Phase 1, Phase 2
4Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinCompletedNCT01322386Phase 1
5Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinRecruitingNCT02137668Phase 1
6Determination of Lysine Requirement in the Parenterally Fed NeonateCompletedNCT00779753
7Esophageal Atresia: Metaplasia, BarrettCompletedNCT02495051
8Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome InfantsCompletedNCT01576003
9Modified Perfusion for Neonatal Aortic Arch ReconstructionCompletedNCT00490256
10Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai PortoenterostomyCompletedNCT00166868
11Survival With Own Liver of Conventional Versus Laparoscopic Kasai for Biliary AtresiaCompletedNCT01063699
12Trail to Investigate the Effectiveness of CoSeal in Reducing Adhesions Following the Kasai Hepatoportoenterostomy for Biliary AtresiaRecruitingNCT01745991
13Molecular Genetics of Heterotaxy and Related Congenital Heart DefectsRecruitingNCT02432079
143D High Resolution Anorectal Manometry in Children After Surgery for Anorectal DisordersRecruitingNCT02296008
15Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)RecruitingNCT00571272
16Long-term Outcome in Patients With Anorectal MalformationsNot yet recruitingNCT02624232
17Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in InfantsTerminatedNCT01062815

Search NIH Clinical Center for Intestinal Atresia


Cochrane evidence based reviews: intestinal atresia

Genetic Tests for Intestinal Atresia

About this section

Anatomical Context for Intestinal Atresia

About this section

MalaCards organs/tissues related to Intestinal Atresia:

33
Liver, Breast, Brain, Heart, Prostate, Bone, Lung

Animal Models for Intestinal Atresia or affiliated genes

About this section

MGI Mouse Phenotypes related to Intestinal Atresia:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053719.0FGF10, FOXC1, PLAGL1, TTC7A
2MP:00053678.7FABP2, FGF10, FOXC1, TTC7A
3MP:00053888.4FGF10, FOXC1, HOXA2, PLAGL1
4MP:00053817.9FGF10, FOXC1, HOXA2, RFX6, TTC7A
5MP:00053857.9FGF10, FOXC1, HOXA2, PLAGL1, TTC7A
6MP:00053786.6FABP2, FGF10, FOXC1, HOXA2, PLAGL1, RFX6

Publications for Intestinal Atresia

About this section

Articles related to Intestinal Atresia:

(show top 50)    (show all 231)
idTitleAuthorsYear
1
Possible sexual transmission of Crimean-Congo hemorrhagic fever. (26972040)
2016
2
Two cases of meningocele and meningoencephalocele in Jeju native pigs. (25889174)
2015
3
Inhaled I^2-Agonist Therapy Increases Functional Residual Capacity in Mechanically Ventilated Children With Respiratory Failure. (25901546)
2015
4
Muscle ultrasound quantifies segmental neuromuscular outcome in pediatric myelomeningocele. (24210858)
2014
5
Infection and propagation of Crimean-Congo hemorrhagic fever virus in embryonated chicken eggs. (23352881)
2013
6
Current options for management of biliary atresia. (23347466)
2013
7
Successful surgical treatment for pulmonary crystal-storing histiocytosis following the onset of gastric non-hodgkin lymphoma. (24369227)
2013
8
Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. (23360251)
2013
9
Reduced placental taurine transporter (TauT) activity in pregnancies complicated by pre-eclampsia and maternal obesity. (23392873)
2013
10
Enhancement of antiviral activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine mutagenesis at adaptive evolution sites. (23269800)
2013
11
In-flight speech intelligibility evaluation of a service member with sensorineural hearing loss: case report. (23025145)
2012
12
Vascular endothelial growth factor -634G/C polymorphism associated with osteonecrosis of the femoral head in a Chinese population. (22612467)
2012
13
Expression of exon-8-skipped kindlin-1 does not compensate for defects of Kindler syndrome. (21146372)
2011
14
Myocardial and cerebral infarction due to massive air embolism following endoscopic retrograde cholangiopancreatography (ERCP). (20195976)
2010
15
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. (19575780)
2009
16
Requirement of Fut8 for the expression of vascular endothelial growth factor receptor-2: a new mechanism for the emphysema-like changes observed in Fut8-deficient mice. (19179362)
2009
17
Selection criteria for genetic assessment of patients with familial melanoma. (19751883)
2009
18
Ultrastructural modification of the endothelium in placental insufficiency and microangiopathies. (19907761)
2009
19
15-lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. (18785202)
2008
20
Self-reported adverse health events following smallpox vaccination in a large prospective study of US military service members. (18382134)
2008
21
Surgical management of BCG vaccine-induced regional axillary lymphadenitis in HIV-infected children. (18686936)
2008
22
Bacterial toxicity of potassium tellurite: unveiling an ancient enigma. (17299591)
2007
23
The A-444C polymorphism of leukotriene C4 synthase gene is associated with IgE antibodies to Dermatophagoides pteronyssinus in a Colombian population. (17291864)
2007
24
A quartet of lateral sinus thrombosis, extradural abscess, subdural abscess and occipital abscess: complications of acute mastoiditis in a pre-adolescent child. (16859571)
2006
25
Nonoverlapping functions of DNA polymerases mu, lambda, and terminal deoxynucleotidyltransferase during immunoglobulin V(D)J recombination in vivo. (16860755)
2006
26
Analysis of ABA hypersensitive germination2 revealed the pivotal functions of PARN in stress response in Arabidopsis. (16359390)
2005
27
Gene transfer of a TIE2 receptor antagonist prevents pulmonary hypertension in rodents. (15678035)
2005
28
Positron tomographic assessment of androgen receptors in prostatic carcinoma. (15726353)
2005
29
Thoracic syringomyelia and suspected multiple sclerosis: cause and effect or coincidence? (15249639)
2004
30
Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. (12909297)
2003
31
Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. (12893435)
2003
32
ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. (12570791)
2003
33
Early reduction, arthrotomy, and cannulated screw fixation in unstable slipped capital femoral epiphysis treatment. (11961454)
2002
34
Submicromolar doses of alkyl-lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells. (12402303)
2002
35
Are hepatitis C infection and C282Y mutation in hemochromatosis gene independent factors for Porphyria cutanea tarda? (12145444)
2002
36
The heavy chain of neonatal Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of beta2-microglobulin association. (12162790)
2002
37
Varicocele as a progressive lesion: positive effect of varicocele repair. (11212075)
2001
38
Inhibitors of bacterial tyrosyl tRNA synthetase: synthesis of carbocyclic analogues of the natural product SB-219383. (11549455)
2001
39
Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. (10965923)
2000
40
Binding thermodynamics at A1 and A2A adenosine receptors. (8890916)
1996
41
Immunohistochemical characterization of keratin expression in clear cell acanthoma. (7547383)
1995
42
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. (8145761)
1993
43
Analysis of oxytocin release by microdialysis and interactions with progesterone. (1626843)
1992
44
Viricidal effect of stimulated human mononuclear phagocytes on human immunodeficiency virus type 1. (1319066)
1992
45
Fitz-Hugh-Curtis Syndrome: pelvic inflammatory disease with an unusual CT presentation. (1522282)
1992
46
Cough-variant asthma in children and adults: case reports and review. (2096171)
1990
47
Diagnosis of occupational dermatitis by general practitioners and employment medical advisors: a pilot study. (2974885)
1988
48
Congenital stationary night blindness with negative electroretinogram. A new classification. (3488053)
1986
49
ERYTHROMELALGIA. (14124085)
1964
50
Remarks on the Sturge-Kalischer-Weber-Dimitri-Krabbe disease. (13301888)
1955

Variations for Intestinal Atresia

About this section

Expression for genes affiliated with Intestinal Atresia

About this section
Search GEO for disease gene expression data for Intestinal Atresia.

Pathways for genes affiliated with Intestinal Atresia

About this section

GO Terms for genes affiliated with Intestinal Atresia

About this section

Biological processes related to Intestinal Atresia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1blood vessel remodelingGO:000197410.0FGF10, FOXC1
2positive regulation of transcription, DNA-templatedGO:00458939.2FGF10, FOXC1, RFX6
3positive regulation of transcription from RNA polymerase II promoterGO:00459448.5FGF10, FOXC1, PLAGL1, RFX6

Molecular functions related to Intestinal Atresia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription regulatory region DNA bindingGO:00442129.6FOXC1, RFX6

Sources for Intestinal Atresia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet